Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
Lymphoma
About this trial
This is an interventional supportive care trial for Lymphoma
Eligibility Criteria
Inclusion Criteria: Patients who have a history of non-Hodgkin B-cell lymphoma and whose disease has been in remission for at least 1 year. Patients who received any anti-CD20 therapy at any time during their treatment for B-cell lymphoma. Patients who are at least 18 years of age. Patients who can provide consent; no legal authorized representative will be able to provide consent on a patient's behalf. Exclusion Criteria: Patients who have received cellular therapy, including chimeric antigen receptor T-cell therapy or any type of hematopoietic cell transplantation. Patients who have received PCV or pneumococcal polysaccharide vaccine within 5 years of screening for enrollment. Patients who are unable to attend follow-up appointments at designated times at MD Anderson. Any vulnerable population patient ((children, pregnant women, cognitively impaired adults, or prisoners)
Sites / Locations
- M D Anderson Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Arm Group A (PCV20)
Arm Group B (PCV20)
Participants will receive 1 dose of the vaccine
Participants will receive 2 doses of the vaccine